Raymond James Financial Services Advisors Inc. bought a new stake in shares of LeMaitre Vascular Inc (NASDAQ:LMAT) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 19,666 shares of the medical instruments supplier’s stock, valued at approximately $658,000.
Several other institutional investors have also made changes to their positions in the stock. Piedmont Investment Advisors LLC bought a new position in shares of LeMaitre Vascular in the second quarter valued at approximately $119,000. Capital Impact Advisors LLC grew its holdings in shares of LeMaitre Vascular by 17.0% in the second quarter. Capital Impact Advisors LLC now owns 51,542 shares of the medical instruments supplier’s stock valued at $1,739,000 after acquiring an additional 7,478 shares in the last quarter. Bessemer Group Inc. grew its holdings in shares of LeMaitre Vascular by 38.1% in the second quarter. Bessemer Group Inc. now owns 19,200 shares of the medical instruments supplier’s stock valued at $643,000 after acquiring an additional 5,300 shares in the last quarter. Creative Planning bought a new position in shares of LeMaitre Vascular in the second quarter valued at approximately $220,000. Finally, Conestoga Capital Advisors LLC grew its holdings in shares of LeMaitre Vascular by 8.9% in the second quarter. Conestoga Capital Advisors LLC now owns 1,392,591 shares of the medical instruments supplier’s stock valued at $46,624,000 after acquiring an additional 113,705 shares in the last quarter. Institutional investors own 79.76% of the company’s stock.
In other LeMaitre Vascular news, CEO George W. Lemaitre sold 35,000 shares of the stock in a transaction on Friday, June 1st. The stock was sold at an average price of $34.50, for a total transaction of $1,207,500.00. Following the completion of the transaction, the chief executive officer now directly owns 3,086,623 shares of the company’s stock, valued at $106,488,493.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO George W. Lemaitre sold 4,821 shares of the stock in a transaction on Monday, June 4th. The shares were sold at an average price of $34.70, for a total value of $167,288.70. Following the transaction, the chief executive officer now directly owns 3,086,623 shares of the company’s stock, valued at $107,105,818.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 160,327 shares of company stock valued at $5,835,918. 20.30% of the stock is owned by corporate insiders.
Several equities analysts have recently issued reports on LMAT shares. BidaskClub lowered LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a report on Friday, June 8th. Roth Capital started coverage on LeMaitre Vascular in a report on Friday, June 8th. They issued a “buy” rating and a $38.00 target price for the company. ValuEngine raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, June 15th. Lake Street Capital started coverage on LeMaitre Vascular in a report on Monday, June 25th. They issued a “buy” rating and a $45.00 target price for the company. Finally, Canaccord Genuity upped their target price on LeMaitre Vascular from $31.00 to $35.00 and gave the company a “hold” rating in a report on Monday, July 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $38.00.
Shares of NASDAQ LMAT opened at $36.05 on Thursday. LeMaitre Vascular Inc has a 1-year low of $28.23 and a 1-year high of $41.28. The firm has a market cap of $688.87 million, a price-to-earnings ratio of 41.92, a PEG ratio of 2.23 and a beta of 0.59.
LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, July 26th. The medical instruments supplier reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.21). LeMaitre Vascular had a net margin of 21.09% and a return on equity of 19.49%. The firm had revenue of $27.02 million for the quarter, compared to the consensus estimate of $27.09 million. During the same period last year, the company posted $0.23 earnings per share. LeMaitre Vascular’s revenue for the quarter was up 4.9% on a year-over-year basis. equities research analysts predict that LeMaitre Vascular Inc will post 1.07 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 6th. Shareholders of record on Wednesday, August 22nd will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.78%. The ex-dividend date of this dividend is Tuesday, August 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 32.56%.
LeMaitre Vascular Profile
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers
Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.